Johnson & Johnson (NYSE:JNJ) Shares Bought by Hendershot Investments Inc.

Hendershot Investments Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 143,899 shares of the company’s stock after purchasing an additional 3,221 shares during the period. Johnson & Johnson makes up approximately 4.4% of Hendershot Investments Inc.’s investment portfolio, making the stock its 3rd largest holding. Hendershot Investments Inc.’s holdings in Johnson & Johnson were worth $23,507,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in JNJ. Price T Rowe Associates Inc. MD grew its stake in shares of Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares during the period. FMR LLC grew its stake in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the period. GQG Partners LLC lifted its holdings in Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after acquiring an additional 1,805,632 shares in the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total value of $2,845,822.20. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock valued at $40,960,735 over the last 90 days. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $168.31 on Tuesday. The stock’s 50-day simple moving average is $176.07 and its 200 day simple moving average is $171.13. The company has a market cap of $440.04 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Barclays assumed coverage on Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price on the stock. SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday. Sanford C. Bernstein cut their price target on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Morgan Stanley cut their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 6th. Finally, Bank of America cut their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $181.75.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.